Genpharmasec Ltd

Genpharmasec Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut for Promoters, Directors, Key Managerial Persons, Designated Persons, and their immediate relatives. It will remain closed from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The exact date of the board meeting to consider these results will be communicated later.

Genpharmasec Ltd. reports no deviation or variation in the use of proceeds from its Rights Issue for the quarter ended March 31, 2026. The funds raised through the Rights Issue, amounting to ₹4,845.05 Lakhs, were utilized as per the objects stated in the Letter of Offer. This confirmation is in compliance with Regulations 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee has reviewed and confirmed the utilization of proceeds.

Genpharmasec Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the re-appointment of M/s. Abhishek M Agrawal & Co. as Internal Auditor for the financial year 2026-2027. The meeting, held on May 21, 2026, commenced at 4:30 p.m. and concluded at 05:15 p.m.

Genpharmasec Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved the re-appointment of M/s. Abhishek M Agrawal & Co. as Internal Auditor for the financial year 2026-2027. The Statutory Auditors, M/s. Bilimoria Mehta & Co., issued an audit report with an unmodified opinion on the financial results.

Genpharmasec Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The meeting will also address other business matters with the Chairman's permission. The trading window for directors and designated persons has been closed from April 1, 2026, until 48 hours after the declaration of the financial results.

Genpharmasec Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. The closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading and Disclosure Practices. The trading window will remain closed from Wednesday, April 01, 2026 till 48 hours after the declaration of Audited Financial Results for the Quarter and Financial year ended March 31, 2026. All Promoter and Promoter group, Directors, KMP's, Designated Persons, Connected Persons of the Company and their immediate relatives are advised not to deal in the securities of the Company during this period. The date of the Board of Directors' meeting to consider and approve the Audited Financial Results will be intimated in due course.

Genpharmasec Ltd, a company based in Mumbai, held a Separate Meeting of Independent Directors on March 24, 2026. The meeting was conducted to review the performance of Non-Independent Directors, the Board as a whole, and the Chairperson of the company. The Independent Directors also assessed the quality, quantity, and timeliness of information flow between the management and the Board. The meeting commenced at 11.00 AM and concluded at 11.30 AM.

Genpharmasec Ltd. announced the approval of its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, at a Board of Directors meeting held on February 09, 2026. The review of the financial results was conducted by Bilimoria Mehta & Co. Chartered Accountants, who found no material misstatements. The company is primarily engaged in a single business segment and has reclassified certain equity shares from Inventories to Financial Investments in accordance with Ind AS 109 and Ind AS 8.

Genpharmasec Ltd has reported its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. The company's total income stands at ₹ 3,251.14 Lakhs, with expenses amounting to ₹ 2,751.96 Lakhs. The profit before tax is ₹ 1,015.27 Lakhs, and the tax expense is ₹ 250.20 Lakhs. The profit for the period is ₹ 765.07 Lakhs. The total comprehensive income for the year is ₹ 745.40 Lakhs. The company's equity share capital is ₹ 5,537.20 Lakhs, and the earning per equity share is ₹ 14.06. The unaudited standalone financial results have been prepared in accordance with the Indian Accounting Standards and reviewed by the Audit Committee.

Genpharmasec Ltd has released a statement confirming no deviation or variation in the use of proceeds from their Rights Issue. The company has utilized the funds as per the objects stated in the Letter of Offer. The Audit Committee has reviewed the statement, and there is no deviation or variation in the utilization of these proceeds. The funds were used for various purposes including acquiring equity shares, repaying or prepaying borrowings, part financing the working capital, meeting general corporate purposes, and meeting the expenses of the issue.